

Ipsen SA (IPN) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/I3121E37C56EN.html
Date:	August 8, 2017
Pages:	65
Price:	US\$ 125.00
ID:	I3121E37C56EN

Ipsen SA (IPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ipsen SA (Ipsen) is a global specialty biotechnology company that manufactures and distributes drugs for the treatment of cancer and endocrine and neurological diseases. The company's portfolio of therapies focus at treating neuroendocrine tumors, prostate, bladder and kidney cancer, pituitary diseases, growth disorders precocious puberty, spasticity, cervical dystonia, hemifacial spasm, blepharospasm, gastrointestinal disorders, neurodegenerative pathologies, gout and other diseases. It has research and development facilities in Les Ulis, France; Oxford, the UK; and Cambridge, the US. The company provides products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France. Ipsen is headquartered in Paris, France.

Ipsen SA Key Recent Developments

Jul 27,2017: Ipsen Delivers Strong Sales Growth of 18.8% in the First Half of 2017 and Upgrades Its Guidance for Full Year 2017

Jun 01,2017: Ipsen To Present New Data of Investigational Compound Ga-OPS201 at ASCO in Line with

its Continued Commitment to Oncology Research

Apr 27,2017: Ipsen Reports Strong First Quarter 2017 Sales Growth of 19,1%1

Apr 14,2017: Ipsen appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer

Mar 02,2017: Ipsen appoints Benoit Hennion as Executive Vice President and President, Primary Care

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

Ipsen SA - Key Facts

Ipsen SA - Key Employees

Ipsen SA - Key Employee Biographies

Ipsen SA - Major Products and Services

Ipsen SA - History

Ipsen SA - Company Statement

Ipsen SA - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Affiliate
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Ipsen SA - Business Description
Ipsen SA - Corporate Strategy
Ipsen SA - SWOT Analysis
SWOT Analysis - Overview
Ipsen SA - Strengths
Ipsen SA - Weaknesses
Ipsen SA - Opportunities
Ipsen SA - Threats
Ipsen SA - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Ipsen SA, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Jul 27, 2017: Ipsen Delivers Strong Sales Growth of 18.8% in the First Half of 2017 and Upgrades Its Guidance for Full Year 2017
Jun 01, 2017: Ipsen To Present New Data of Investigational Compound Ga-OPS201 at ASCO in Line with its Continued Commitment to Oncology Research
Apr 27, 2017: Ipsen Reports Strong First Quarter 2017 Sales Growth of 19,1%
Apr 14, 2017: Ipsen appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer
Mar 02, 2017: Ipsen appoints Benoit Hennion as Executive Vice President and President, Primary Care
Feb 23, 2017: Ipsen delivers strong 2016 results and expects further sales growth and margin enhancement for 2017
Feb 06, 2017: Ipsen announces appointment of Dr. Sotirios G. Stergiopoulos as Head of Global Medical Affairs
Jan 20, 2017: Ipsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises
Dec 12, 2016: Ipsen announces departure of EVP of R&D and chief scientific officer
Dec 12, 2016: Claude Bertrand to step down as Executive Vice President, R&D, Chief Scientific Officer of Ipsen

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData

Contact Us
Disclaimer

LIST OF TABLES

Ipsen SA, Key Facts
Ipsen SA, Key Employees
Ipsen SA, Key Employee Biographies
Ipsen SA, Major Products and Services
Ipsen SA, History
Ipsen SA, Subsidiaries
Ipsen SA, Affiliate
Ipsen SA, Joint Venture
Ipsen SA, Key Competitors
Ipsen SA, Ratios based on current share price
Ipsen SA, Annual Ratios
Ipsen SA, Annual Ratios (Cont.1)
Ipsen SA, Annual Ratios (Cont.2)
Ipsen SA, Interim Ratios
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Ipsen SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Ipsen SA, Performance Chart (2012 - 2016)
Ipsen SA, Ratio Charts
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

UCB Pharma SA
Sanofi
OSE Immunotherapeutics
Onxeo SA
Mylan NV
Laboratoires Pierre Fabre SA
GlaxoSmithKline Plc
Genfit SA
Fareva Holding
Eurofins Cerep SA
Avadel Pharmaceuticals Plc

I would like to order:

Product name: Ipsen SA (IPN) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/I3121E37C56EN.html>
Product ID: I3121E37C56EN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/I3121E37C56EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**